IBRX ImmunityBio, Inc.
Company Analysis
Latest News
ImmunityBio Reports Voting Results from 2026 Annual Shareholder Meeting
ImmunityBio (IBRX) announced the official voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Shareholders approved all proposals...
ImmunityBio Jumps 11%, Led by 431% Revenue Surge and ANKTIVA Sales
ImmunityBio (IBRX) shares gained 11% following the release of its fourth-quarter financial results. Net product revenue surged 431% year-over-year to $38.3...
🟢 Immunitybio Inc is trading 5.06% up today amid a broader market rally and geopolitical de-escalation
Immunitybio Inc is trading at $7.27 (+5.06%) as the stock rebounds alongside a broader recovery in U.S. equity markets. • The upward move aligns with gains in...
🟢 Immunitybio Inc is trading 4.5% up today, recovering from last week's macro-driven selloff
Immunitybio Inc is trading 4.5% up at $7.23 as it recovers from last week’s macro-driven selloff in alignment with a broader market rebound. • The upward move...
🔴 Immunitybio Inc is trading 5.5% down today on macro pressure and reduced rate cut hopes
Immunitybio Inc is trading 5.5% down at $6.89 as U.S. equities face a broad selloff and risk assets come under pressure. • The decline appears macro-driven,...
🔴 Immunitybio Inc is trading 4.1% down today amid broad market selloff
Immunitybio Inc is trading 4.1% down at $6.99 today, primarily driven by a broad market selloff and general risk-off sentiment. • The stock's decline appears...
ImmunityBio Shares Sink, FDA Questions ANKTIVA Bladder Cancer Trial Data
ImmunityBio (IBRX) shares declined on May 29, 2026. The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental application to expand the...
🔴 IBRX is trading 4.7% down today on class action reminders and profit taking
IBRX is trading 4.7% down at $7.36 as traders react to ongoing securities class action reminders and volatility-driven profit taking. • Legal firms are...
🔴 IBRX is trading 6.2% down today amid class action legal overhang and profit taking
IBRX is trading 6.2% down today at $7.24 as investors react to ongoing securities class action reminders and profit taking following recent volatility. •...
🔴 IBRX is trading 5.1% down today amid legal overhangs and profit taking
IBRX is trading 5.1% down today at $7.33 amid ongoing legal overhangs and profit taking following recent volatility. • The decline follows a series of...
🟢 IBRX is trading 10.9% up today as lead-plaintiff deadline for securities class actions approaches
IBRX is trading 10.9% up today at $8.01 as investors react to the May 26, 2026, lead-plaintiff deadline for multiple securities class actions tied to Anktiva...
ImmunityBio's Legal Cloud Lifts Slightly on Deadline Day — But Can the Stock Escape Its Courtroom Overhang?
Shares of ImmunityBio (IBRX) ticked up 3.3% to $7.46 on May 26, 2026 — the very day a critical lead-plaintiff deadline expires in securities fraud class...
🟢 IBRX is trading 3.3% up today as lead-plaintiff deadline for class action hits
IBRX is trading 3.3% up today at $7.46 as investors digest the May 26, 2026, lead-plaintiff filing deadline for ongoing securities class actions. • The stock...
🔴 IBRX is trading 5.6% down today as profit-taking continues after FDA-driven rally
IBRX is trading 5.6% down today at $7.31 as investors continue to lock in gains following a significant rally triggered by the FDA's sBLA acceptance for...
🔴 IBRX is trading 4.2% down today as profit-taking extends after FDA sBLA acceptance rally
IBRX is trading 4.2% down at $7.42 as traders extend profit-taking following the sharp FDA sBLA acceptance rally linked to ANKTIVA plus BCG. • The stock...
🔴 IBRX is trading 6.5% down today on profit-taking after its FDA sBLA acceptance rally
IBRX is trading at $7.53 (-6.52%) as the stock undergoes a sharp pullback following a rally sparked by the FDA’s acceptance of its supplemental BLA for ANKTIVA...
🔴 IBRX is trading 3.9% down today on profit-taking after its FDA sBLA acceptance rally
IBRX is trading 3.9% down at $7.74 today as the stock undergoes profit-taking and consolidation following a sharp rally triggered by positive regulatory...
🟢 IBRX is trading 9.3% up today on FDA acceptance of ANKTIVA sBLA for bladder cancer
IBRX is trading at $8.48 (+9.28%) following the FDA's acceptance of ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The filing...
🟢 IBRX is trading 7.2% up today after FDA accepts ANKTIVA sBLA for bladder cancer
IBRX is trading 7.2% up at $8.32 in pre-market after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The...
🟢 IBRX is trading 4.5% up today after FDA accepts ANKTIVA expansion filing
IBRX is trading at $8.11 (+4.5%) after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The filing seeks to...